ArrayExpress Uploader04051SRC-1 scrambledtamoxifen for 120 minSRC-1 siRNAuntreatedSRC-1 scrambledtamoxifen for 120 minSRC-1 siRNAtamoxifen for 120 minsSRC-1 scrambledtamoxifen for 120 minSRC-1 siRNAtamoxifen for 120 minSRC-1 scrambleduntreatedSRC-1 siRNAuntreatedSRC-1 siRNAuntreatedSRC-1 scrambleduntreatedSRC-1 scrambleduntreatedSRC-1 siRNAuntreatedSRC-1 scrambleduntreatedSRC-1 scrambledtamoxifen for 120 minarrayexpress_sid4The development of breast cancer resistance to endocrine therapy results from an increase in cellular plasticity leading to the...22072566E-GEOD-28645/profile/8773/arrayexpressuploader214breastbreast cancercancerestrogenproteinDec.12, 2014Falsesrc1-gene-regulation-in-endocrine-resistant-breastE-GEOD-28645_A-AFFY-44SRC1 gene regulation in endocrine resistant breast cancer cellsSep.16, 2014The development of breast cancer resistance to endocrine therapy results from an increase in cellular plasticity leading to the development of a steroid independent tumour. The p160 steroid coactivator protein SRC-1, through interactions with developmental proteins and other non-steroidal transcription factors drives this tumour adaptability. Here, using discovery studies we identify ADAM22, a non-protease member of the ADAMs family, as a direct target of SRC-1, independent of estrogen receptor(ER). Molecular, cellular, in vivo and clinical studies confirmed SRC-1 as a regulator of ADAM22 and established a role for ADAM22 in endocrine resistant tumour progression. ADAM22 has the potential to act as a therapeutic drug target and a companion predictive biomarker in the treatment of endocrine resistant breast cancer. 14 samples representing 4 conditions were analysed. Samples were transfected with either a siRNA targetting SRC1 or a control scrambled siRNA. Samples were subject to tamoxifen treatment or untreated.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-28645humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-28645/samples/